Combined radiotherapy and hormone therapy in unfavorable intermediate risk prostate cancer

Cover Page

Cite item

Full Text

Abstract

Background. Currently, the group of intermediate risk prostate cancer (PC) includes 2 subgroups - favorable and unfavorable intermediate risk according to the National Comprehensive Cancer Network (NCCN) classification. The optimal scope of therapy is not defined for the unfavorable intermediate risk subgroup. In particular, the need for and duration of hormone therapy (HT) during combined radiotherapy (CRT) have not yet been determined.

Aim. To perform a comparative analysis of the efficacy and toxicity of CRT in patients with unfavorable intermediate risk treated with and without HT.

Materials and methods. Eighty-four (84) patients with unfavorable intermediate risk PC were treated with CRT at the clinic of the A.F. Tsyb Medical Radiological Research Center between May 2016 and December 2020. Patients were divided into two groups: external beam radiation therapy + brachytherapy (n = 40) and external beam radiation therapy + brachytherapy + HT (n = 44). Conformal external beam radiation therapy was delivered with conventional fractionation to a total dose of 44-46 Gy and the 192Ir high-dose rate brachytherapy was delivered with a single fraction of 15 Gy. Median duration of HT consisting of gonadotropin-releasing hormone agonist was 6 months. Median age was 65.2 years (range: 49-80 years). Median follow-up was 58.1 months (range: 18.6-83.7 months).

Results. With a median follow-up of 4.8 years, progression-free survival was 95 % and 97.6 % in the external beam radiation therapy + brachytherapy group and external beam radiation therapy + brachytherapy + HT group, respectively (p = 0.578). The break between treatment stages of more than 28 days was associated with a statistically significant increase in the risk of PC recurrence (p = 0.007). Overall survival for the external beam radiation therapy + brachytherapy group versus external beam radiation therapy + brachytherapy + HT group was 97.5 and 93.2 % (p = 0.376), respectively.

Late genitourinary toxicity was grade I in 8 (9.5 %) patients and grade II in 1 (1.2 %) patient. Urethral stricture developed in 3 (3.6 %) patients. Late gastrointestinal toxicity was grade I in 7 (8.3 %) patients and grade II in 1 (1.2 %) patient. There were no statistically significant differences in the incidence of late complications between groups with and without HT. There was a statistically significant (p = 0.049) effect of prostate volume on the incidence of late radiation proctitis.

Conclusion. There were no statistically significant differences in progression-free survival and overall survival in patients with unfavorable intermediate risk PC who received external beam radiation therapy + brachytherapy with or without HT. The incidence and severity of adverse events were acceptable and allowed patients with PC to maintain high quality of life.

About the authors

K. S. Makarova

A.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Author for correspondence.
Email: mks.40@mail.ru
ORCID iD: 0000-0001-7192-3193
SPIN-code: 6327-6528

Kseniya S. Makarova.

10 Marshala Zhukova St., Obninsk 249031

Russian Federation

Yu. V. Gumenetskaya

A.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0002-8163-8406

10 Marshala Zhukova St., Obninsk 249031

Russian Federation

V. A. Biryukov

A.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0002-6750-521X

10 Marshala Zhukova St., Obninsk 249031

Russian Federation

T. A. Rodina

A.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0003-2361-1915

10 Marshala Zhukova St., Obninsk 249031

Russian Federation

A. B. Galitsyna

Obninsk Institute for Nuclear Power Engineering — branch of the National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)

1 Territoriya Studgorodok, Obninsk 249039

Russian Federation

E. O. Shchukina

A.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0001-5431-8696

10 Marshala Zhukova St., Obninsk 249031

Russian Federation

O. B. Karyakin

A.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0002-6112-2840

10 Marshala Zhukova St., Obninsk 249031

Russian Federation

S. A. Ivanov

A.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center, Ministry of Health of Russia; Peoples' Friendship University of Russia

ORCID iD: 0000-0001-7689-6032

10 Marshala Zhukova St., Obninsk 249031; 6 Miklukho-Maklay St., 117198 Moscow

Russian Federation

A. D. Kaprin

Peoples' Friendship University of Russia; National Medical Research Radiological Center, Ministry of Health of Russia; P.A. Hertzen Moscow Oncology Research Institute — branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0001-8784-8415

6 Miklukho-Maklay St., 117198 Moscow; 4 Koroleva St., Obninsk 249036; 3 2nd Botkinskiy Proezd, Moscow 125284

Russian Federation

References

  1. State of oncological care in Russia in 2021. Eds.: A.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 239 p. (In Russ.).
  2. Malignant tumors in Russia in 2021 (morbidity and mortality). Eds.: A. D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 252 p. (In Russ.).
  3. Fletcher S.A., Landenberg N., Cole A.P. et al. Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer Prostatic Dis 2020;23(1):81-7. doi: 10.1038/s41391-019-0157-y
  4. NCCN Guidelines, Version 1.2023. Prostate cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
  5. Zumsteg Z.S., Spratt D.E., Pei I. et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol 2013;64(6):895-902. doi: 10.1016/j.eururo.2013.03.033
  6. Prostate Cancer Guidelines, 2021. (In Russ.).
  7. Castle K.O., Hoffman K.E., Levy L.B. et al. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys 2013;85(3):693-9. doi: 10.1016/j.ijrobp.2012.06.030
  8. Mendez L.C., Martell K., Warner A. et al. Does ADT benefit unfa-vourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A pro-pensity-score matched analysis. Radiother Oncol 2020;150:195-200. doi: 10.1016/j.radonc.2020.06.039
  9. Vigneault E., Morton G., Parulekar W.R. et al. Randomised phase II feasibility trial of image-guided external beam radiotherapy with or without high dose rate brachytherapy boost in men with in-termediate-risk prostate cancer (CCTG PR15/ NCT01982786). Clin Oncol 2018;30(9):527-33. doi: 10.1016/j.clon.2018.05.007
  10. Morton G.C., Loblaw D.A., Sankreacha R. et al. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life. Int J Radiat Oncol Biol Phys 2010;77(3):811-7. doi: 10.1016/j.ijrobp.2009.05.054
  11. Andruska N., Fischer-Valuck B.W., Carmona R. et al. Is the addition of brachytherapy and/or androgen deprivation therapy associated with improved overall survival in unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy? Brachytherapy 2022;21(5):617-25. doi: 10.1016/j.brachy.2022.04.001
  12. Mohiuddin J.J., Narayan V., Venigalla S. et al. Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer. Brachytherapy 2019;18(3):322-31. doi: 10.1016/j.brachy.2019.01.016
  13. Keating N.L., O'Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24(27):4448-56. doi: 10.1200/JCO.2006.06.2497
  14. Bosco C., Bosnyak Z., Malmberg A. et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 2015;68(3):386-96. doi: 10.1016/j.eururo.2014.11.039
  15. Scailteux L.M., Naudet F., Alimi Q. et al. Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: a systematic review with direct and network meta-analyses of randomized controlled trials and observational studies. Medicine 2016;95(24):e3873. doi: 10.1097/MD.0000000000003873
  16. Beyer D.C., McKeough T., Thomas T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005;61(5):1299-305. doi: 10.1016/j.ijrobp.2004.08.024
  17. Pickles T., Tyldesley S., Hamm J. et al. Brachytherapy for intermediate risk prostate cancer, androgen deprivation and the risk of death. Int J Radiat Oncol Biol Phys 2017;100(1):45-52. doi: 10.1016/j.ijrobp.2017.08.042
  18. Yamazaki H., Masui K., Suzuki G. et al. High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer. Sci Rep 2021;11(1):6165. doi: 10.1038/s41598-021-85682-9
  19. Makhnev V.V., Benzion D.L. Early and late toxicity of concomitant radiation therapy in prostate cancer according to the materials of Sverdlovsk Regional Oncology Center. Proceedings of the First International Forum of Oncology and Radiology. Moscow, 2018. (In Russ.).
  20. Shahid N., Loblaw A., Chung H.T. et al. Long-term toxicity and health-related quality of life after single-fraction high dose rate brachytherapy boost and hypofractionated external beam radiotherapy for intermediate-risk prostate cancer. Clin Oncol 2017;29(7):412-20. doi: 10.1016/j.clon.2017.01.042
  21. Astrom L., Grusell E., Sandin F. et al. Two decades of high dose rate brachytherapy with external beam radiotherapy for prostate cancer. Radiother Oncol 2018;127(1):81-7. doi: 10.1016/j.radonc.2017.12.025

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.